Yifan Pharmaceutical (002019.SZ) Subsidiary Evive Receives EMA Approval for Ryzneuta, a Treatment for Neutropenia
Non-Pegylated G-CSF Receptor Agonist Clears Regulatory Hurdle
Ryzneuta (efbemalenograstim alfa), developed by Evive Biotechnology, received marketing authorization from the European Medicines Agency (EMA) on March 21, 2024. This approval signifies the arrival of a new non-pegylated option for the treatment of chemotherapy-induced neutropenia (CIN). Unlike existing treatments, Ryzneuta is designed to reduce the risk of related allergic reactions by eliminating the PEGylation process and Tween-80 component. This allows cancer patients to maintain safer and more stable white blood cell counts during chemotherapy.
Efficacy and Safety Demonstrated Through Phase 3 Clinical Data
Ryzneuta's approval is based on the results of a global clinical development program consisting of 12 studies involving over 1,200 subjects. In particular, a Phase 3 trial (NCT02872103) comparing Ryzneuta to placebo and a Phase 3 trial (NCT03252431) comparing Ryzneuta to pegfilgrastim, the existing first-generation standard treatment, played a crucial role. The study results showed that Ryzneuta was effective in reducing the duration of severe neutropenia and the incidence of febrile neutropenia, and its safety profile was also demonstrated. This provides strong evidence that Ryzneuta has equivalent or superior value and can replace or supplement existing standard therapies in clinical practice.
Partnerships Established and Commercialization Strategy for European Market Penetration
Ryzneuta will be distributed throughout Europe through a strategic partnership between its parent company, Yifan Pharmaceutical, and Evive Biotechnology. Exclusive distribution agreements have been signed with local pharmaceutical companies, including APOGEPHA in Germany, Switzerland, and Austria; Molteni in Italy and Poland; and KALTEQ in Greece and Cyprus. This localized distribution network is expected to accelerate the translation of regulatory approval into actual prescription sales. In addition, a distribution agreement has been signed with Lenis Group for eight Eastern European countries, aggressively expanding its market presence in Europe.
Differentiated Competitiveness and Limitations in the Mature Neutropenia Market
The global neutropenia treatment market is currently estimated at $700 million to $3.2 billion, and existing pegfilgrastim biosimilars, such as Neulasta, hold a significant market share. In addition, next-generation competing drugs, such as Rolvedon (eflapegrastim) developed by Hanmi Pharmaceutical, are also present, making the market highly competitive. Ryzneuta aims to leverage its unique positioning as the first non-pegylated long-acting treatment. However, it must overcome significant hurdles, including price negotiations with European national health authorities and the process of obtaining reimbursement coverage. Therefore, the scope of reimbursement and the price level obtained in each country over the next one to two years will be key indicators for measuring Ryzneuta's commercial success.
Evive Biotechnology's Ryzneuta has obtained marketing authorization from the European Medicines Agency (EMA), following its approval by the U.S. FDA, completing the final regulatory steps for entry into major global markets. By demonstrating non-inferiority to pegfilgrastim in reducing the duration of severe neutropenia in Phase 3 clinical trials, Ryzneuta has secured clinical credibility compared to existing biosimilars and competing treatments such as Rolvedon. The global market size is approximately $700 million to $3.2 billion, and in the long term, Ryzneuta is expected to penetrate the market by replacing existing pegylated G-CSF products based on the uniqueness of its non-pegylated platform. However, the company's ability to negotiate prices in each country and diversify its distribution network will determine the initial pace of commercialization, so it is necessary to monitor changes in the financial contribution of the parent company, Yifan Pharmaceutical, based on future sales growth.
Source: EMA (ema)